GFM
PTCT icon

GF Fund Management’s PTC Therapeutics PTCT Stock Holding History

GF Fund Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Sell
1,753
-50
-3% -$3.61K ﹤0.01% 301
2026
Q1 		$123K Buy
1,803
+226
+14% +$16K ﹤0.01% 321
2025
Q4 		$120K Sell
1,577
-132
-8% -$9.59K ﹤0.01% 334
2025
Q3 		$105K Sell
1,709
-265
-13% -$13.8K ﹤0.01% 333
2025
Q2 		$96.4K Hold
1,974
– – ﹤0.01% 369
2025
Q1 		$101K Buy
1,974
+355
+22% +$17.7K ﹤0.01% 363
2024
Q4 		$73.1K Buy
+1,619
New +$69.3K ﹤0.01% 356

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

GF Fund Management's PTCT Position: Q2 2026 in Review

GF Fund Management reduced its PTC Therapeutics (PTCT) stake by 2.8% in Q2 2026, selling an estimated $3.61K and leaving 1,753 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #301.

GF Fund Management first reported a position in PTCT in Q4 2024 and has held it in 7 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • GF Fund Management held 1,753 shares of PTC Therapeutics worth $143K as of Q2 2026.
  • GF Fund Management sold 50 PTC Therapeutics shares in Q2 2026, an estimated $3.61K.
  • PTC Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #301 holding.
  • GF Fund Management first reported a position in PTC Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.